Cargando…
Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
BACKGROUND: The D-dimer (DD) assay is an essential biological test for the diagnosis and monitoring of thrombotic conditions. DD testing is usually not performed as part of the routine laboratory management of patients with hemophilia (PWH). There is an increasing concern about the risk of thromboti...
Autores principales: | Iarossi, Michael, Lambert, Catherine, Hermans, Cedric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732800/ https://www.ncbi.nlm.nih.gov/pubmed/36474347 http://dx.doi.org/10.1177/10760296221143382 |
Ejemplares similares
-
Disruptive technology and hemophilia care: The multiple impacts of emicizumab
por: Hermans, Cedric, et al.
Publicado: (2021) -
Regression Analysis to Estimate the Factor VIII Activity of Patients with Hemophilia A Without Inhibitor who Received Emicizumab Therapy
por: Hatayama, Yuki, et al.
Publicado: (2022) -
Challenges of biological monitoring in a hemophilia A patient without inhibitors on emicizumab undergoing major orthopedic surgery: a case report
por: Guillaume, Louise, et al.
Publicado: (2021) -
Emicizumab Associated Rhabdomyolysis in Hemophilia A
por: Wilson, Joseph A., et al.
Publicado: (2020) -
The effect of emicizumab and bypassing agents in patients with hemophilia – An in vitro study
por: Schultz, Nina Haagenrud, et al.
Publicado: (2021)